Vyome Holdings Dives into $57 Billion Immunology Market with Selective JAK Inhibitor Licensing Deal from Tata’s Impetis Biosciences
Mumbai/New York – Nasdaq-listed Vyome Holdings has made a significant strategic move, licensing two preclinical selective Janus kinase (JAK) inhibitor assets from Impetis Biosciences, a pioneering enterprise within India’s venerable…
